Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
Journal
Journal of Gastroenterology and Hepatology (Australia)
Journal Volume
36
Journal Issue
8
Pages
2247-2254
Date Issued
2021
Author(s)
Hsieh M.-H.
Bair M.-J.
Tsai P.-C.
Tseng K.-C.
Lo C.-C.
Chen C.-Y.
Kuo H.-T.
Hung C.-H.
Lai H.-C.
Peng C.-Y.
Wang J.-H.
Chen J.-J.
Lee P.-L.
Chien R.-N.
Yang C.-C.
Lo G.-H.
Yan S.-L.
Lin C.-Y.
Su W.-W.
Chu C.-H.
Chen C.-J.
Tung S.-Y.
Tai C.-M.
Lin C.-W.
Cheng P.-N.
Chiu Y.-C.
Wang C.-C.
Cheng J.-S.
Tsai W.-L.
Lin H.-C.
Huang Y.-H.
Yeh M.-L.
Huang C.-F.
Huang J.-F.
Dai C.-Y.
Yu M.-L.
Chuang W.-L.
T-COACH investigators
Abstract
BACKGROUND AND AIM: Chronic hepatitis C virus (HCV) infection is associated with impaired renal function. The aim of this study is to explore the risk of and factors associated with end-stage renal diseases (ESRD) under maintenance dialysis among HCV patients after anti-HCV therapy. METHODS: A total of 12 696 HCV-infected patients with interferon-based therapy, including 9679 (76.2%) achieving sustained virological response (SVR), were enrolled from 23 hospitals in Taiwan. RESULTS: , instead of SVR, were the significant risk factors for developing ESRD with maintenance dialysis after anti-HCV therapy (adjusted hazard ratio 7.75 and 9.78). CONCLUSION: Diabetes and baseline impaired renal function were strongly associated with progression to ESRD with maintenance dialysis among chronic HCV-infected patients after antiviral therapy.
SDGs
Publisher
John Wiley and Sons Inc
Type
journal article